Get the Stockscreener App
3.39
5.57%
-0.20
Pre-market:
3.28
-0.11
-3.24%
Xenetic Biosciences Inc Stock (XBIO) Latest News
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success - StockTitan
Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Milton Daily Standard
Can Xenetic's DNase I Innovation Finally Crack the Solid Tumor Barrier for CAR-T Therapy? - StockTitan
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 21.4% in January - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January - Defense World
Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology - ACCESS Newswire
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com
XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com
XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World
Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan
Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan
Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK
Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada
Xenetic and PeriNess partner for cancer treatment trials - Investing.com
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire
Xenetic Biosciences (STU:3XB0) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 43.2% in November - Defense World
HC Wainwright Reiterates Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Bio's DNase I Shows Breakthrough in Colorectal Cancer Treatment Efficacy | XBIO Stock News - StockTitan
XBIOXenetic Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire
Xenetic Bio's DNase I + CAR T Cell Therapy Shows Breakthrough in Melanoma Treatment | XBIO Stock News - StockTitan
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks
Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan
Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):